VIR vs ADMA vs REGN vs GRFS

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus -7. 6% for Vir Biotechnology, Inc. (VIR). Grifols, S. A. (GRFS) offers the better valuation at 12. 0x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate Vir Biotechnology, Inc. (VIR) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 12. 0x versus Regeneron Pharmaceuticals, Inc. at 17. 1x. On forward P/E, ADMA Biologics, Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -78. 4% for Vir Biotechnology, Inc. (VIR). Over 10 years, the gap is even starker: REGN returned +90. 0% versus GRFS's -35. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 81β versus Vir Biotechnology, Inc. 's 2. 05β — meaning VIR is approximately 155% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 115% for Grifols, S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus -7. 6% for Vir Biotechnology, Inc. (VIR). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -638. 9% for Vir Biotechnology, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -682. 7% for VIR. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ADMA Biologics, Inc.

(ADMA) trades at 8. 9x forward P/E versus 15. 3x for Regeneron Pharmaceuticals, Inc. — 6. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 165. 6% to $22. 50.

In this comparison, GRFS (2.

6% yield), REGN (0. 5% yield) pay a dividend. VIR, ADMA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Grifols, S.

A. (GRFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12), 2. 6% yield). Vir Biotechnology, Inc. (VIR) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GRFS: -35. 4%, VIR: -33. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VIR is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; GRFS is a small-cap deep-value stock. GRFS pays a dividend while VIR, ADMA, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.